Regulation of signaling pathways by Ampelopsin (Dihydromyricetin) in different cancers: exploring the highways and byways less travelled
| Autor: | Edyta Pawlak-Adamska, Uteuliyev Yerzhan Sabitaliyevich, Muhammad Zahid Qureshi, Saleh S. Alhewairini, Seda Avnioğlu, Rukset Attar, Fatima Tahir, Aleksandra Buha, Hina Salahuddin, Aima Adylova, Sundas Fayyaz |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Flavonoids
0303 health sciences Natural product Flavonols Chemistry 030302 biochemistry & molecular biology Cancer Apoptosis General Medicine medicine.disease stat 3. Good health Ampelopsin 03 medical and health sciences chemistry.chemical_compound Growth factor receptor Neoplasms Cancer research medicine Animals Humans Tumor growth Signal transduction Signal Transduction |
| Zdroj: | Cellular and molecular biology (Noisy-le-Grand, France). 65(7) |
| ISSN: | 1165-158X |
| Popis: | Ampelopsin or Dihydromyricetin is gradually emerging as a high-quality natural product because of its ability to modulate wide-ranging signaling pathways. Ampelopsin (Dihydromyricetin) has been reported to effectively modulate growth factor receptor (VEGFR2 and PDGFRβ) mediated signaling, TRAIL/TRAIL-R pathway, JAK/STAT and mTOR-driven signaling in different cancers. Ampelopsin (Dihydromyricetin) has also been shown to exert inhibitory effects on the versatile regulators which trigger EMT (Epithelial-to-Mesenchymal Transition). Findings obtained from in-vitro studies are encouraging and there is a need to comprehensively analyze how Ampelopsin (Dihydromyricetin) inhibits tumor growth in different cancer models. Better knowledge of efficacy of Ampelopsin (Dihydromyricetin) in tumor bearing mice will be helpful in maximizing its translational potential. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|